Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Cardiology Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Visualizing the Future of Presbyopia

By: Francis S. Mah, MD; Daniel H. Chang, MD; and Marjan Farid, MD

Webinar Credits: 1.25

Presbyopia is a natural result of aging, and eventually affects all individuals who reach an advanced age. This webinar includes discussions on the shortcomings of current treatments, clinical trial data on the emerging pharmaceutical options for the treatment of presbyopia, and patient selection for these novel therapies.

Expiration Date: Thursday, December 30, 2021
Release Date: December 29, 2020

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Describe the underlying mechanisms of presbyopic changes.
  • Interpret the clinical trial experience published in the literature with pharmaceutical and nonpharmaceutical presbyopia-correcting (PC) options.
  • Differentiate among the pharmacological properties of newly emerging presbyopia correcting drops and their mechanisms of action (MOA).
  • Explain how PC drops are likely to affect categories of patients based on individual characteristics.
  • Compare the side effects of pharmaceutical approaches to presbyopia correction with other treatment options to debate the pros and cons of each strategy.

Accreditation and Designation Statement

This educational activity is provided by Evolve Medical Education.

Accreditation Statement
Evolve Medical Education, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve Medical Education, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM

Recommended internet speed 5Mbps+

 

Faculty and Disclosures

FACULTY


Francis S. Mah, MD
Program Chair
Program Moderator
Director, Cornea and External Disease
Co-Director, Refractive Surgery
Scripps Clinic
La Jolla, CA

 

 
Marjan Farid, MD
Professor of Ophthalmology
School of Medicine
Vice Chair, Ophthalmic Faculty
Director, Cornea/External Disease,
Cataract, and Refractive Surgery
Gavin Herbert Eye Institute
University of California, Irvine
Irvine, CA

 


Daniel H. Chang, MD
Cataract and Refractive Surgeon
Clinical Research Director
Empire Eye and Laser Center
Bakersfield, CA


DISCLOSURE POLICY

It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Francis S. Mah, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau:Alcon; Allergan; Bausch + Lomb; Johnson &Johnson Vision; Glaukos; Eyenovia; iView; Nevakar; Novartis; Ocular Science; and RxSight.

Marjan Farid, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Bio-Tissue, CorneaGen, Dompe, Eyepoint, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Orasis, and Zeiss

Daniel H. Chang, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Carl Zeiss Meditec, Johnson & Johnson Vision, Omega Ophthalmics, and Mynosys. Grant/Research Support: Acufocus, Johnson & Johnson Vision, and Mynosys.  Shareholder: Omega Ophthalmics.

The Evolve Medical Education staff and planners have no financial relationships with commercial interests.

Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Allergan.

Pretest

  • a. Not at all confidentb. Not very confidentc. Neutrald. Confidente. Extremely confident

Video Resources

Next

Welcome to Visualizing the Future of Presbyopia – Live.

Please click “Begin Program” to open the Zoom session for the live program.

BackNext
You Passed!

Congratulations!

You have already passed this test with a score of:

80%

Back